LOW RISK ILLICIT DRUG LEVEL MONITORING

Information

  • Research Project
  • 6073462
  • ApplicationId
    6073462
  • Core Project Number
    R43DA013055
  • Full Project Number
    1R43DA013055-01
  • Serial Number
    13055
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/1999 - 25 years ago
  • Project End Date
    3/31/2000 - 25 years ago
  • Program Officer Name
    SINGH, HARI
  • Budget Start Date
    9/30/1999 - 25 years ago
  • Budget End Date
    3/31/2000 - 25 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/30/1999 - 25 years ago
Organizations

LOW RISK ILLICIT DRUG LEVEL MONITORING

The research described in this proposal details a procedure for detecting and quantifying Illicit Drugs using an immunoassay coupled with surface enhanced Raman scattering (SERS) spectroscopy. The technique has the advantage of high sensitivity due to the use of SERS. In addition, the unique surface sensitive detection of SERS means that the assay can be read without washing away the indicator antigens. This makes it possible to easily automate this method for rapid screening of large numbers of samples in a microwell plate format. The assays will be demonstrated with microwell plates that have been modified with a SERS active colloid. The SERS surface will be treated with anti-illicit drug, dye-tagged drugs, and processed to form a pretreated plate. These will represent part of the commercial product to be developed and will be tested for durability. The analysis will be performed by sample introduction onto the modified microwell plate. Only those drugs that are captured and displace the reporter conjugates on the surface will produce SERS spectra from the microtiter wells. Dye drug conjugates that are not captured are not observed as their spectra are not enhanced by the SERS effect. We will investigate several dye conjugates that have absorptions in the red to enhance the sensitivity of our technique. We will use both a 633 nm HeNe laser system for the analysis. Tests will be made with whole blood, saliva, and perspiration. PROPOSED COMMERCIAL APPLICATION Current methods for immunoassay are difficult, time consuming, and require hazardous radioactive reagents. The washing step that we eliminate makes automation difficult in current methods since most samples requires strengent washing to remove the tagged drugs. The technique proposed here will provide a quantitative result without washing and will be very easily automated for large scale rapid analysis. We are proposing to look at illicit drug analysis, however, the methodology can be adapted to all immunoassays.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R43
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    DELTANU, LLC
  • Organization Department
  • Organization DUNS
  • Organization City
    LARAMIE
  • Organization State
    WY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    82070
  • Organization District
    UNITED STATES